Kai-Lyn Loh1, Qingshu Lu2, Donald Tan3, Audrey Chia4. 1. Singapore National Eye Center, Singapore. 2. Singapore Clinical Research Institute, Singapore; Center for Quantitative Medicine, Duke-National University of Singapore Graduate Medical School, Singapore. 3. Singapore National Eye Center, Singapore; Singapore Eye Research Institute, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 4. Singapore National Eye Center, Singapore; Singapore Eye Research Institute, Singapore. Electronic address: wla_chia@yahoo.com.
Abstract
PURPOSE: To investigate variables associated with myopic progression despite treatment in the Atropine in the Treatment of Myopia Study. DESIGN: Retrospective cohort study. METHODS:Two hundred of 400 children were randomized to receive atropine 1% in 1 eye only in this institutional study. Children were followed up with cycloplegic autorefraction every 4 months over 2 years. Children whose myopia progressed by more than 0.5 diopter (D) in the atropine-treated eye at 1 year were classified as being progressors. RESULTS: Among the 182 children still in the study at 1 year, 22 (12.1%) were classified as progressors. Univariate analysis suggested these children tended to be younger (8.5 ± 1.4 years vs 9.3 ± 1.5 years; P = .023), to have higher myopic spherical equivalent (SE) at baseline (-3.6 ± 1.3 D vs -2.8 ± 1.4 D; P = .015), and to have 2 myopic parents (77.3% vs 48.1%; P = .012). In nonprogressors, the myopia progression at 1 year was less in the atropine-treated eyes compared with the untreated fellow eye (+0.16 ± 0.37 D vs -0.73 ± 0.48 D; P < .001), but in progressors, progression was more similar between eyes (-0.92 ± 0.31 D vs -1.06 ± 0.44 D; P = .363). Regression analysis showed that the risk of being a progressor was 40% lower with each year of increased age, 43% lower for every 1.0 D less in myopia at baseline, and 59% lower for every 1.0 D less in myopic change in the untreated eyes over the first year. CONCLUSIONS: Doctors and parents need to be aware that there is a small group of children (younger, with higher myopia, and greater tendency of myopic progression) who may still progress while receiving atropine treatment.
RCT Entities:
PURPOSE: To investigate variables associated with myopic progression despite treatment in the Atropine in the Treatment of Myopia Study. DESIGN: Retrospective cohort study. METHODS: Two hundred of 400 children were randomized to receive atropine 1% in 1 eye only in this institutional study. Children were followed up with cycloplegic autorefraction every 4 months over 2 years. Children whose myopia progressed by more than 0.5 diopter (D) in the atropine-treated eye at 1 year were classified as being progressors. RESULTS: Among the 182 children still in the study at 1 year, 22 (12.1%) were classified as progressors. Univariate analysis suggested these children tended to be younger (8.5 ± 1.4 years vs 9.3 ± 1.5 years; P = .023), to have higher myopic spherical equivalent (SE) at baseline (-3.6 ± 1.3 D vs -2.8 ± 1.4 D; P = .015), and to have 2 myopic parents (77.3% vs 48.1%; P = .012). In nonprogressors, the myopia progression at 1 year was less in the atropine-treated eyes compared with the untreated fellow eye (+0.16 ± 0.37 D vs -0.73 ± 0.48 D; P < .001), but in progressors, progression was more similar between eyes (-0.92 ± 0.31 D vs -1.06 ± 0.44 D; P = .363). Regression analysis showed that the risk of being a progressor was 40% lower with each year of increased age, 43% lower for every 1.0 D less in myopia at baseline, and 59% lower for every 1.0 D less in myopic change in the untreated eyes over the first year. CONCLUSIONS: Doctors and parents need to be aware that there is a small group of children (younger, with higher myopia, and greater tendency of myopic progression) who may still progress while receiving atropine treatment.
Authors: Henry H L Chan; Kai Yip Choi; Alex L K Ng; Bonnie N K Choy; Jonathan Cheuk Hung Chan; Sonia S H Chan; Serena Z C Li; Wing Yan Yu Journal: Sci Rep Date: 2022-07-08 Impact factor: 4.996
Authors: Jeffrey J Walline; Kristina B Lindsley; S Swaroop Vedula; Susan A Cotter; Donald O Mutti; Sueko M Ng; J Daniel Twelker Journal: Cochrane Database Syst Rev Date: 2020-01-13
Authors: Virgilio Galvis; Alejandro Tello; M Margarita Parra; Jesus Merayo-Lloves; Jaime Larrea; Carlos Julian Rodriguez; Paul Anthony Camacho Journal: Med Hypothesis Discov Innov Ophthalmol Date: 2016